AI assistant
GlaxoSmithKline PLC — Remuneration Information 2014
Jan 15, 2014
5262_dirs_2014-01-15_1e27aa5c-f0c8-4020-914e-072af20fcf70.html
Remuneration Information
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 7652X
GlaxoSmithKline PLC
15 January 2014
This announcement replaces the original announcement released on 3 January 2014 at 9.43am (RNS No: 8550W).
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
I give below details of changes in the Directors' interests in the Ordinary Shares and American Depositary Shares (ADSs) of GlaxoSmithKline plc (the Company).
On 31 December 2013, the Company's Non-Executive Directors were provisionally allocated the following awards over Ordinary Shares and ADSs in the Company through the annual reinvestment of dividends paid throughout 2013; calculated using an average price of £16.073 per Ordinary Share and $53.170 per ADS:
| Non-Executive Director | Ordinary Shares | No. of ADSs |
| Sir Christopher Gent | 4,466.364 | |
| Prof Sir Roy Anderson | 685.862 | |
| Dr Stephanie Burns | 538.531 | |
| Stacey Cartwright | 125.504 | |
| Lynn Elsenhans | 78.145 | |
| Judy Lewent | 80.720 | |
| Sir Deryck Maughan | 1,379.853 | |
| Dr Daniel Podolsky | 968.774 | |
| Tom de Swaan | 998.268 | |
| Jing Ulrich | 24.625 | |
| Hans Wijers | 3.630 | |
| Sir Robert Wilson | 1,032.435 |
The Company and the Non-Executive Directors were informed of these allocations on 2 January 2014.
This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Sonja Arsenić
Corporate Secretariat
15 January 2014
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSDMGMMVKKGDZM